HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCall, A. M. Articles by Weiner, L. M. Search for Related Content PubMed PubMed Citation Articles by McCall, A. M. Articles by Weiner, L. M.

Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity¹

Adrian M. McCall^2,3,*, Lillian Shahied^3,*, Anne R. Amoroso^*, Eva M. Horak^*, Heidi H. Simmons^*, Ulrick Nielson, Gregory P. Adams^*, Robert Schier^4,, James D. Marks and Louis M. Weiner^5,*

^* Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111; and Department of Anesthesia, University of California, San Francisco, CA 94110

We tested the hypothesis that bispecific Abs (Bsab) with increased binding affinity for tumor Ags augment retargeted antitumor cytotoxicity. We report that an increase in the affinity of Bsab for the HER2/neu Ag correlates with an increase in the ability of the Bsab to promote retargeted cytotoxicity against HER2/neu-positive cell lines. A series of anti-HER2/neu extracellular domain-directed single-chain Fv fragments (scFv), ranging in affinity for HER2/neu from 10^-7 to 10^-11 M, were fused to the phage display-derived NM3E2 human scFv. NM3E2 associates with the extracellular domain of human FcRIII (CD16). The resulting series of Bsab promoted cytotoxicity of SKOV3 human ovarian carcinoma cells overexpressing HER2/neu by human PBMC preparations containing CD16-positive NK cells. The affinity for HER2/neu clearly influenced the ability of the Bsab to promote cytotoxicity of ⁵¹Cr-labeled SKOV3 cells. Lysis was 6.5% with an anti-HER2/neu K_D = 1.7 x 10^-7 M, 14.5% with K_D = 5.7 x 10^-9 M, and 21.3% with K_D = 1.7 x 10^-10 M at 50:1 E:T ratios. These scFv-based Bsab did not cross-link receptors and induce leukocyte calcium mobilization in the absence of tumor cell engagement. Thus, these novel Bsab structures should not induce the dose-limiting cytokine release syndromes that have been observed in clinical trials with intact IgG Bsab. Additional manipulations in Bsab structure that improve selective tumor retention or facilitate the ability of Bsab to selectively cross-link tumor and effector cells at tumor sites should further improve the utility of this therapeutic strategy.

This article has been cited by other articles:

				Y. Tang, J. Lou, R. K. Alpaugh, M. K. Robinson, J. D. Marks, and L. M. Weiner Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen J. Immunol., September 1, 2007; 179(5): 2815 - 2823. [Abstract] [Full Text] [PDF]

				C. Germain, C. Larbouret, V. Cesson, A. Donda, W. Held, J.-P. Mach, A. Pelegrin, and B. Robert MHC Class I-Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells Clin. Cancer Res., October 15, 2005; 11(20): 7516 - 7522. [Abstract] [Full Text] [PDF]

				L. S. Shahied, Y. Tang, R. K. Alpaugh, R. Somer, D. Greenspon, and L. M. Weiner Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format J. Biol. Chem., December 24, 2004; 279(52): 53907 - 53914. [Abstract] [Full Text] [PDF]

				S. M. Kipriyanov, B. Cochlovius, H. J. Schafer, G. Moldenhauer, A. Bahre, F. Le Gall, S. Knackmuss, and M. Little Synergistic Antitumor Effect of Bispecific CD19 x CD3 and CD19 x CD16 Diabodies in a Preclinical Model of Non-Hodgkin's Lymphoma J. Immunol., July 1, 2002; 169(1): 137 - 144. [Abstract] [Full Text] [PDF]